X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dishman Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ADCOCK INGRAM
Jun-14
DISHMAN PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs374367-   
Low Rs129265-   
Sales per share (Unadj.) Rs197.8109.1-  
Earnings per share (Unadj.) Rs21.2-27.5-  
Cash flow per share (Unadj.) Rs34.7-22.8-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.985.7-  
Shares outstanding (eoy) m80.69168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.9 44.0%   
Avg P/E ratio x11.9-11.5 -103.3%  
P/CF ratio (eoy) x7.2-13.9 -52.3%  
Price / Book Value ratio x1.43.7 37.9%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,30653,291 38.1%   
No. of employees `0000.84.3 19.3%   
Total wages/salary Rs m5,3553,345 160.1%   
Avg. sales/employee Rs Th19,252.74,290.3 448.7%   
Avg. wages/employee Rs Th6,459.5779.1 829.1%   
Avg. net profit/employee Rs Th2,064.1-1,081.1 -190.9%   
INCOME DATA
Net Sales Rs m15,96118,418 86.7%  
Other income Rs m265129 205.8%   
Total revenues Rs m16,22618,547 87.5%   
Gross profit Rs m4,103-3,192 -128.6%  
Depreciation Rs m1,091795 137.2%   
Interest Rs m944499 189.3%   
Profit before tax Rs m2,334-4,357 -53.6%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624272 229.1%   
Profit after tax Rs m1,711-4,641 -36.9%  
Gross profit margin %25.7-17.3 -148.4%  
Effective tax rate %26.7-6.2 -427.7%   
Net profit margin %10.7-25.2 -42.5%  
BALANCE SHEET DATA
Current assets Rs m11,01813,490 81.7%   
Current liabilities Rs m9,5177,590 125.4%   
Net working cap to sales %9.432.0 29.4%  
Current ratio x1.21.8 65.1%  
Inventory Days Days110111 99.6%  
Debtors Days Days35124 28.1%  
Net fixed assets Rs m16,3047,863 207.3%   
Share capital Rs m16186 188.7%   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,51614,456 100.4%   
Long term debt Rs m4,1895,080 82.5%   
Total assets Rs m29,80527,309 109.1%  
Interest coverage x3.5-7.7 -44.9%   
Debt to equity ratio x0.30.4 82.1%  
Sales to assets ratio x0.50.7 79.4%   
Return on assets %8.9-15.2 -58.7%  
Return on equity %11.8-32.1 -36.7%  
Return on capital %17.5-19.8 -88.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,7861,572 177.2%  
From Investments Rs m-1,529-483 316.7%  
From Financial Activity Rs m-9414,611 -20.4%  
Net Cashflow Rs m3165,700 5.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.06 Rs / ZAR

Compare DISHMAN PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare DISHMAN PHARMA With: ALEMBIC PHARMA  UNICHEM LAB  PLETHICO PHARMA  AJANTA PHARMA  PANACEA BIOTECH  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

Laurus Labs Ltd (IPO)

Dec 6, 2016

Equitymaster analyses Initial Public Offering (IPO) of Laurus Labs, one of the leading supplier of APIs for ARVs and Hepatitis C.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS